D. Western Therapeutics Institute, Inc. (TYO:4576)
Japan
· Delayed Price · Currency is JPY 126.00
-2.00 (-1.56%)
Jun 13, 2025, 3:30 PM JST
TYO:4576 Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 463.52 | 471 | 428 | 448 | 414 | 355 | Upgrade
|
| Revenue Growth (YoY) | 4.87% | 10.05% | -4.46% | 8.21% | 16.62% | -38.79% | Upgrade
|
| Cost of Revenue | 47.81 | 47 | 36 | 28 | 21 | 17 | Upgrade
|
| Gross Profit | 415.71 | 424 | 392 | 420 | 393 | 338 | Upgrade
|
| Selling, General & Admin | 285.09 | 265 | 258 | 255 | 248 | 253 | Upgrade
|
| Research & Development | 1,163 | 1,367 | 930 | 469 | 316 | 350 | Upgrade
|
| Operating Expenses | 1,449 | 1,634 | 1,190 | 726 | 565 | 604 | Upgrade
|
| Operating Income | -1,033 | -1,210 | -798 | -306 | -172 | -266 | Upgrade
|
| Interest Expense | -6.24 | -5 | -2 | -3 | -4 | -4 | Upgrade
|
| Interest & Investment Income | 0.53 | - | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -5.37 | 1 | 6 | 33 | 17 | -6 | Upgrade
|
| Other Non Operating Income (Expenses) | -12.5 | -13 | -2 | -20 | - | -14 | Upgrade
|
| EBT Excluding Unusual Items | -1,056 | -1,227 | -796 | -296 | -159 | -290 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -12 | -100 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.02 | -2 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -6 | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | -44 | - | - | Upgrade
|
| Other Unusual Items | -60.61 | -60 | -12 | - | - | - | Upgrade
|
| Pretax Income | -1,118 | -1,289 | -826 | -440 | -159 | -290 | Upgrade
|
| Income Tax Expense | 1.6 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Earnings From Continuing Operations | -1,120 | -1,290 | -827 | -441 | -160 | -291 | Upgrade
|
| Minority Interest in Earnings | - | - | 15 | 12 | 12 | 15 | Upgrade
|
| Net Income | -1,120 | -1,290 | -812 | -429 | -148 | -276 | Upgrade
|
| Net Income to Common | -1,120 | -1,290 | -812 | -429 | -148 | -276 | Upgrade
|
| Shares Outstanding (Basic) | 38 | 35 | 32 | 30 | 29 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 35 | 32 | 30 | 29 | 27 | Upgrade
|
| Shares Change (YoY) | 18.95% | 10.51% | 7.22% | 1.04% | 7.96% | 3.41% | Upgrade
|
| EPS (Basic) | -29.40 | -36.73 | -25.55 | -14.47 | -5.05 | -10.16 | Upgrade
|
| EPS (Diluted) | -29.40 | -36.73 | -25.55 | -14.47 | -5.05 | -10.16 | Upgrade
|
| Free Cash Flow | - | -1,308 | -598 | -363 | -178 | -221 | Upgrade
|
| Free Cash Flow Per Share | - | -37.24 | -18.82 | -12.25 | -6.07 | -8.13 | Upgrade
|
| Gross Margin | 89.69% | 90.02% | 91.59% | 93.75% | 94.93% | 95.21% | Upgrade
|
| Operating Margin | -222.82% | -256.90% | -186.45% | -68.30% | -41.55% | -74.93% | Upgrade
|
| Profit Margin | -241.55% | -273.88% | -189.72% | -95.76% | -35.75% | -77.75% | Upgrade
|
| Free Cash Flow Margin | - | -277.71% | -139.72% | -81.03% | -42.99% | -62.25% | Upgrade
|
| EBITDA | -983.33 | -1,161 | -750 | -260 | -127 | -222 | Upgrade
|
| EBITDA Margin | -212.14% | -246.50% | -175.23% | -58.04% | -30.68% | -62.53% | Upgrade
|
| D&A For EBITDA | 49.48 | 49 | 48 | 46 | 45 | 44 | Upgrade
|
| EBIT | -1,033 | -1,210 | -798 | -306 | -172 | -266 | Upgrade
|
| EBIT Margin | -222.82% | -256.90% | -186.45% | -68.30% | -41.55% | -74.93% | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.